1063 related articles for article (PubMed ID: 32800967)
1. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
2. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
4. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
5. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
6. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
7. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
8. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
10. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
12. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
Magnusson P; Gadler F; Liv P; Mörner S
J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
[TBL] [Abstract][Full Text] [Related]
13. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
Rowin EJ; Burrows A; Madias C; Estes NAM; Link MS; Maron MS; Maron BJ
Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008123. PubMed ID: 32897759
[TBL] [Abstract][Full Text] [Related]
15. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
16. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
Maron BJ; Maron MS
Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
18. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.
Vriesendorp PA; Schinkel AF; Van Cleemput J; Willems R; Jordaens LJ; Theuns DA; van Slegtenhorst MA; de Ravel TJ; ten Cate FJ; Michels M
Am Heart J; 2013 Sep; 166(3):496-502. PubMed ID: 24016499
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.
Hen Y; Tsugu-Yagawa M; Iguchi N; Utanohara Y; Takada K; Machida H; Takara A; Teraoka K; Inoue K; Takamisawa I; Takayama M; Yoshikawa T
Heart Vessels; 2018 Jan; 33(1):49-57. PubMed ID: 28766047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
